Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
BeOne Medicines AG is a biotechnology firm focused on developing innovative therapies for cancer and autoimmune diseases, leveraging its proprietary platform for drug discovery. The company's unique competitive advantage lies in its advanced biomarker-driven approach, which enhances the precision of its therapies, particularly in the European and North American markets.
BeOne generates revenue primarily through the sale of its proprietary therapies, which command premium pricing due to their efficacy and safety profiles. The company also engages in collaborative agreements with larger pharmaceutical firms, providing a steady stream of income while sharing development costs.
FDA approval of new therapies, particularly in oncology
Partnership announcements with larger pharmaceutical companies
Clinical trial results that exceed market expectations
Changes in reimbursement policies affecting pricing power
Regulatory changes impacting drug approval processes
Technological disruption in drug development methodologies
Emergence of generic competitors post-patent expiration
Rapid advancements in alternative therapies, such as gene editing
Potential liquidity issues if cash flow does not meet expectations
Rising operational costs impacting margins
moderate - The biotechnology sector can be sensitive to economic cycles, as funding and investment in R&D may fluctuate with economic conditions.
Interest rates affect BeOne's cost of capital; higher rates may increase financing costs for R&D, potentially impacting growth plans and valuations.
minimal - The company has a manageable debt-to-equity ratio of 0.43, indicating low reliance on external credit.
growth - Investors are typically attracted to BeOne for its high revenue growth potential and innovative pipeline.
high - The stock exhibits high volatility due to the nature of biotech stocks and reliance on clinical trial outcomes.